Home
Norwegian Multiple Sclerosis Competence Centre and Research Group

Clinical Research

Backgound and vision

Clinical research aims to explore the progression of the disease and to evaluate new potential treatment options for patients with MS.

Ongoing projects

The efficacy and safety of hematopoietic stem cell treatment in Multiple Sclerosis-The first Norwegian results

Autologous stem cell treatment is a promising treatment option in MS, but so far relatively few patients have been treated in Norway.The object of this study is to evaluate and describe the outcome of HSCT treatment for all Norwegian patients receiving HSCT from Jan. 2015 to Jan. 2018. The method is retrospective evaluation of medical records. The study is approved by the Regional Ethical Committee and written consent has been collected from all patients. 

Time frame for the project is until 2020.

Please contact: Silje Stokke Kvistad (PhD-candidate)
E-mail: sgns@helse-bergen.no
Phone: +47 55 97 58 47

Norwegian Multiple Sclerosis Competence Centre
Dept. of Neurology
Haukeland University Hospital
5021 Bergen

Cognitive function in the early stages of MS

Objective: Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) test battery and evaluation of the extent of cognitive dysfunction in a Norwegian population of MS patients in the early stages of the disease.

Methods: MS-patients with onset of symptoms no more than 3 years prior to diagnosis 2014-2017 are tested with BICAMS at baseline and again after 12 and 24 months. 3T MRI of brain and spinal cord is taken around the same time for evaluation of radiological markers for cognitive dysfunction.

Timeframe: Funding from Helse Vest 01.05.17-30.04.20

Please contact: Ellen Skorve (Phd-candidate) 
E-mail: ellen-skorve@helse-bergen.no

Norwegian Multiple Sclerosis Competence Centre
Dept. of Neurology
Haukeland University Hospital
5021 Bergen